A meta-analysis demonstrates that angiotensin converting enzyme (ACE) inhibitors provide a survival benefit in patients with diabetic nephropathy, whereas no such evidence exists for angiotensin II receptor antagonists (AIIRAs).
A meta-analysis demonstrates that angiotensin converting enzyme (ACE) inhibitors provide a survival benefit in patients with diabetic nephropathy, whereas no such evidence exists for angiotensin II receptor antagonists (AIIRAs). Both classes of drugs prevent progression of nephropathy and promote regression to normoalbuminuria.
The meta-analysis included almost exclusively placebo-controlled trials, making comparison of the relative effects of ACE inhibitors and AIIRAs on survival difficult, according to the study authors. "True differences in the relative effects of ACE inhibitors and AIIRAs can be established only by adequately powered trials that directly compare the two agents, which unfortunately are not available," they write.
Forty-three trials in which ACE inhibitors or AIIRAs were compared with placebo or each other in patients with micro- or macroalbuminuria were identified through a search of Medline, Embase, and a renal group trial register. Thirty-six trials compared ACE inhibitors with placebo (N=4,008), 4 compared AIIRAs with placebo (N=3,331), and 3 compared ACE inhibitors with AIIRAs (N=206). Additional study data were obtained from study authors, when possible, to evaluate all outcomes of interest (eg, all-cause death and renal outcomes).
Compared with placebo, ACE inhibitors were associated with reductions in a doubling of serum creatinine concentration and the development of end-stage renal disease, which approached but did not achieve significance. ACE inhibitors significantly reduced the risk of progression from micro- to macroalbuminuria by 55% (95% CI, 0.28–0.71) and significantly increased the rate of regression from micro- to normoalbuminuria by more than 3-fold (RR=3.42; 95% CI, 1.95–5.99).
Three trials in which AIIRAs were compared with placebo showed a significant 22% reduction in the risk of end-stage renal disease (95% CI, 0.67–0.91) and a significant 21% reduction in the risk of doubling of serum creatinine (95% CI, 0.67–0.93) with AIIRAs. Three placebo-controlled trials also demonstrated a significant 51% decrease in the risk of progression from micro- to macroalbuminuria with therapy (95% CI, 0.32–0.75), and 2 trials showed a significant increase in the rate of regression from micro- to normoalbuminuria (RR=1.42; 95% CI, 1.05–1.93).
The 3 trials in which ACE inhibitors were compared with AIIRAs did not report on all-cause mortality, end-stage renal disease, or doubling of serum creatinine; in 1 trial, a trend existed favoring ACE inhibitors in reducing the risk of progression from micro- to macroalbuminuria (RR=0.16; 95% CI, 0.02–1.44).
The effect of ACE inhibitors on all-cause mortality did not vary according to type of diabetes, presence or absence of hypertension, or microalbuminuria compared with macroalbu-minuria at baseline.
The authors concluded that the designs of the trials, including the patient populations studied, their risk of renal disease at baseline, and achieved blood pressure differences compared with placebo, may explain some of the differences observed in the results between the 2 classes of agents.
SOURCE Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ [serial online]. October 2004;329:1-12. Available from BMJ Publishing Group, Limited, London, England. Accessed February 23, 2005.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.